Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells - PubMed (original) (raw)
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells
Peter E Fecci et al. Clin Cancer Res. 2006.
Abstract
Purpose: Elevated proportions of regulatory T cells (T(reg)) are present in patients with a variety of cancers, including malignant glioma, yet recapitulative murine models are wanting. We therefore examined T(regs) in mice bearing malignant glioma and evaluated anti-CD25 as an immunotherapeutic adjunct.
Experimental design: CD4+CD25+Foxp3+GITR+ T(regs) were quantified in the peripheral blood, spleens, cervical lymph nodes, and bone marrow of mice bearing malignant glioma. The capacities for systemic anti-CD25 therapy to deplete T(regs), enhance lymphocyte function, and generate antiglioma CTL responses were assessed. Lastly, survival and experimental allergic encephalitis risks were evaluated when anti-CD25 was combined with a dendritic cell-based immunization targeting shared tumor and central nervous system antigens.
Results: Similar to patients with malignant glioma, glioma-bearing mice show a CD4 lymphopenia. Additionally, CD4+CD25+Foxp3+GITR+ T(regs) represent an increased fraction of the remaining peripheral blood CD4+ T cells, despite themselves being reduced in number. Similar trends are observed in cervical lymph node and spleen, but not in bone marrow. Systemic anti-CD25 administration hinders detection of CD25+ cells but fails to completely eliminate T(regs), reducing their number only moderately, yet eliminating their suppressive function. This elimination of T(reg) function permits enhanced lymphocyte proliferative and IFN-gamma responses and up to 80% specific lysis of glioma cell targets in vitro. When combined with dendritic cell immunization, anti-CD25 elicits tumor rejection in 100% of challenged mice without precipitating experimental allergic encephalitis.
Conclusions: Systemic anti-CD25 administration does not entirely eliminate T(regs) but does prevent T(reg) function. This leads to safe enhancement of tumor immunity in a murine glioma model that recapitulates the tumor-induced changes to the CD4 and T(reg) compartments seen in patients with malignant glioma.
Similar articles
- Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.
Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Fecci PE, et al. Clin Cancer Res. 2007 Apr 1;13(7):2158-67. doi: 10.1158/1078-0432.CCR-06-2070. Clin Cancer Res. 2007. PMID: 17404100 - Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood.
Ahn JS, Krishnadas DK, Agrawal B. Ahn JS, et al. Int Immunol. 2007 Mar;19(3):227-37. doi: 10.1093/intimm/dxl139. Epub 2007 Feb 7. Int Immunol. 2007. PMID: 17289657 - Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.
Ohmura Y, Yoshikawa K, Saga S, Ueda R, Kazaoka Y, Yamada S. Ohmura Y, et al. Oncol Rep. 2008 May;19(5):1265-70. Oncol Rep. 2008. PMID: 18425386 - CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus.
Kuhn A, Beissert S, Krammer PH. Kuhn A, et al. Arch Dermatol Res. 2009 Jan;301(1):71-81. doi: 10.1007/s00403-008-0891-9. Epub 2008 Nov 5. Arch Dermatol Res. 2009. PMID: 18985367 Review. - Dendritic cell-based glioma immunotherapy (review).
Yamanaka R, Yajima N, Abe T, Tsuchiya N, Homma J, Narita M, Takahashi M, Tanaka R. Yamanaka R, et al. Int J Oncol. 2003 Jul;23(1):5-15. Int J Oncol. 2003. PMID: 12792771 Review.
Cited by
- A Combination of Systemic and Intracranial Anti-CD25 Immunotherapy Elicits a Long-Time Survival in Murine Model of Glioma.
Poirier MD, Haban H, El Andaloussi A. Poirier MD, et al. J Oncol. 2009;2009:963037. doi: 10.1155/2009/963037. Epub 2010 Mar 21. J Oncol. 2009. PMID: 20339520 Free PMC article. - Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes.
Sayour EJ, Mendez-Gomez HR, Mitchell DA. Sayour EJ, et al. Int J Mol Sci. 2018 Sep 23;19(10):2890. doi: 10.3390/ijms19102890. Int J Mol Sci. 2018. PMID: 30249040 Free PMC article. Review. - Anti-inflammatory treatments during the chronic phase of spinal cord injury improve locomotor function in adult mice.
Arnold SA, Hagg T. Arnold SA, et al. J Neurotrauma. 2011 Sep;28(9):1995-2002. doi: 10.1089/neu.2011.1888. Epub 2011 Sep 6. J Neurotrauma. 2011. PMID: 21740131 Free PMC article. - Investigation of immunosuppressive mechanisms in a mouse glioma model.
Ksendzovsky A, Feinstein D, Zengou R, Sharp A, Polak P, Lichtor T, Glick RP. Ksendzovsky A, et al. J Neurooncol. 2009 May;93(1):107-14. doi: 10.1007/s11060-009-9884-6. Epub 2009 May 9. J Neurooncol. 2009. PMID: 19430886 - PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.
Oh T, Ivan ME, Sun MZ, Safaee M, Fakurnejad S, Clark AJ, Sayegh ET, Bloch O, Parsa AT. Oh T, et al. Immunotherapy. 2014;6(6):737-53. doi: 10.2217/imt.14.35. Immunotherapy. 2014. PMID: 25186604 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials